無料レポート プレゼントキャンペーン 実施中 : メールサービスに新規登録いただいた方にご用意した無料レポートをご提供

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界のヘルスケア産業におけるバイオテクノロジー関連契約:契約条件・合意内容

Global Biotech Partnering Terms and Agreements 2012-2018: Deal Trends, Players and Financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 362388
出版日 ページ情報 英文 1000+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.93円で換算しております。
Back to Top
世界のヘルスケア産業におけるバイオテクノロジー関連契約:契約条件・合意内容 Global Biotech Partnering Terms and Agreements 2012-2018: Deal Trends, Players and Financials
出版日: 2018年05月01日 ページ情報: 英文 1000+ Pages
概要

当レポートでは、世界のヘルスケア産業におけるバイオテクノロジー関連の各種提携契約について調査し、近年における各種契約の動向、大規模契約の概要、提携契約にもっとも積極的な事業者のプロファイル、契約内容を詳細に示したディレクトリなどをまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 バイオテクノロジー関連契約の動向

  • イントロダクション
  • 過去のバイオテクノロジー関連提携契約
  • 提携契約にもっとも活発に取り組む事業者
  • バイオテクノロジー関連提携契約:契約タイプ別
  • バイオテクノロジー関連提携契約:治療領域別
  • バイオテクノロジー関連提携契約:技術タイプ別
  • 提携契約条件
    • 取引総額
    • 前金支払額
    • 目標達成報奨金
    • ロイヤルティ料率

第3章 主なバイオテクノロジー関連提携契約

  • イントロダクション
  • 主要契約:取引額別

第4章 提携契約にもっとも積極的な事業者

  • イントロダクション
  • もっとも積極的な事業者
  • もっとも積極的な事業者のプロファイル

第5章 契約ディレクトリ

  • イントロダクション
  • 契約ディレクトリ

第6章 バイオテクノロジー関連提携契約:技術タイプ別

第7章 リソースセンター

  • オンラインリソース
  • イベント
  • 文献

付録

  • 付録1:バイオテクノロジー関連提携契約:企業名順(A〜Z)
  • 付録2:バイオテクノロジー関連提携契約:開発ステージ別
  • 付録3:バイオテクノロジー関連提携契約:取引タイプ別
  • 付録4:バイオテクノロジー関連提携契約:治療領域別
  • 付録5:取引タイプの定義

Wildwood Venturesについて

図表一覧

目次
Product Code: CP1013

Global Biotech Partnering Terms and Agreements 2012 to 2018 report provides a detailed understanding and analysis of how and why companies enter Biotech partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Biotech agreements announced in the life sciences since 2012.

The report takes the reader through a comprehensive review Biotech deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Biotech partnering deals.

The report presents financial deal term values for Biotech deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Biotech partnering field; both the leading deal values and most active Biotech dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 7,000 online deal records of actual Biotech deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Biotech dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Biotech dealmaking since 2012, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Biotech deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 most active companies in Biotech dealmaking with a brief summary followed by a comprehensive listing of Biotech deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of Biotech partnering deals signed and announced since Jan 2012, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of Biotech partnering deals signed and announced since Jan 2012. The chapter is organized by specific technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by Biotech partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The repor t also includes numerous tables and figures that illustrate the trends and activities in Biotech partnering and dealmaking since 2012.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Biotech technologies and products.

Key benefits

Global Biotech Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Biotech deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Biotech agreements with real life case studies
  • Detailed access to actual Biotech contracts entered into by leading biopharma companies
  • Identify most active Biotech dealmakers since 2012
  • Insight into terms included in a Biotech partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Global Biotech Partnering 2012-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Biotech trends and structure of deals entered into by leading companies worldwide.

Biotech Partnering Terms and Agreements includes:

  • Trends in Biotech dealmaking in the biopharma industry since 2012
  • Analysis of Biotech deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Biotech deals
  • Access to Biotech contract documents
  • Leading Biotech deals by value since 2012
  • Most active Biotech dealmakers since 2012

In Global Biotech Partnering 2012-2018: Deal trends, players, financials and forecasts , the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Biotech Partnering 2012-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 7,000 Biotech deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global Biotech Partnering 2012-2018: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of Biotech deal trends since 2012
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Biotech agreements with real life case studies
  • Detailed access to actual Biotech contracts entered into by leading biopharma companies
  • Identify most active Biotech dealmakers since 2012
  • Insight into terms included in a Biotech partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Biotech dealmaking

  • 2.1. Introduction
  • 2.2. Biotech partnering over the years
  • 2.3. Most active Biotech dealmakers
  • 2.4. Biotech partnering by deal type
  • 2.5. Biotech partnering by therapy area
  • 2.6. Biotech partnering by technology type
  • 2.7. Deal terms for Biotech partnering
    • 2.7.1 Biotech partnering headline values
    • 2.7.2 Biotech deal upfront payments
    • 2.7.3 Biotech deal milestone payments
    • 2.7.4 Biotech royalty rates

Chapter 3 - Leading Biotech deals

  • 3.1. Introduction
  • 3.2. Top Biotech deals by value

Chapter 4 - Most active Biotech dealmakers

  • 4.1. Introduction
  • 4.2. Most active Biotech dealmakers
  • 4.3. Most active Biotech partnering company profiles

Chapter 5 - Biotech contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Biotech contracts dealmaking directory

Chapter 6 - Biotech dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Biotech deals by company A-Z
  • Appendix 2 - Biotech deals by stage of development
  • Appendix 3 - Biotech deals by deal type
  • Appendix 4 - Biotech deals by therapy area
  • Appendix 5 - Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Biotech partnering since 2012
  • Figure 2: Active Biotech dealmaking activity since 2012
  • Figure 3: Biotech partnering by deal type since 2012
  • Figure 4: Biotech partnering by disease type since 2012
  • Figure 5: Biotech partnering by technology type since 2012
  • Figure 6: Biotech deals with a headline value
  • Figure 7: Biotech deals with an upfront value
  • Figure 8: Biotech deals with a milestone value
  • Figure 9: Biotech deals with a royalty rate value
  • Figure 10: Top Biotech deals by value since 2012
  • Figure 11: Most active Biotech dealmakers since 2012
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top